Boston Scientific Corporation ($BSX) Stock Forecast: Down 2.2% Today

What is Boston Scientific Corporation?

Boston Scientific (BSX) is a leading medical device company that specializes in innovative solutions for various medical conditions. The overall market for medical products has been competitive and dynamic, with companies constantly striving to develop cutting-edge technologies to meet the evolving needs of healthcare.

Why is Boston Scientific Corporation going down?

BSX stock is down 2.2% on Aug 6, 2025 14:45

• The bearish movement in BSX today could be attributed to investors comparing the stock with GE HealthCare Technologies (GEHC) and potentially finding more value in the latter.
• The overly optimistic views of Wall Street analysts on BSX might have raised concerns among investors about the stock's actual performance, leading to a sell-off.
• Investors may have also reacted to broader market trends or specific industry news impacting medical product companies, causing a negative sentiment towards BSX in today's trading session.

BSX Price Chart

BSX Technical Analysis

BSX News

GEHC vs. BSX: Which Stock Is the Better Value Option?

Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies ( GEHC Quick QuoteGEHC - ) and Boston Scientific ( BSX Quick QuoteBSX - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

https://www.zacks.com/stock/news/2649813/gehc-vs-bsx-which-stock-is-the-better-value-option

Is It Worth Investing in Boston Scientific ( BSX ) Based on Wall Street's Bullish Views?

The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

https://www.zacks.com/stock/news/2648960/is-it-worth-investing-in-boston-scientific-bsx-based-on-wall-streets-bullish-views

Trending Today

Chemours Company (The) ($CC) Stock Forecast: Down 5.9% Today

Clover Health Investments Crop. ($CLOV) Stock Forecast: Down 22.9% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.0% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.0% Today

Apple Inc. ($AAPL) Stock Forecast: Up 5.0% Today

NiSource Inc ($NI) Stock Forecast: Down 2.6% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 5.0% Today

Iron Mountain Incorporated (Delaware)Common Stock REIT ($IRM) Stock Forecast: Down 1.5% Today

Rivian Automotive Inc. ($RIVN) Stock Forecast: Down 5.2% Today

TPG ($TPG) Stock Forecast: Up 5.2% Today

Boston Scientific Corporation Price History

24.06.2025 - BSX Stock was down 1.9%

• BSX reported strong Q2 earnings, exceeding estimates and raising its full-year outlook.
• Despite the positive earnings, the stock saw a bearish movement, possibly due to profit-taking by investors who had already factored in the positive news.
• The market's negative reaction may stem from concerns about BSX's ability to maintain its growth momentum in the future, leading some investors to sell off their positions.
• Broader market conditions or sector-specific factors could have influenced the bearish movement in BSX, despite the favorable earnings report.

04.03.2025 - BSX Stock was down 5.4%

• BSX stock saw a -1.55% decline, ending the day at $98.50.
• The stock has been consistently decreasing, with a 3.16% drop in the current session and a 1.95% decrease over the past month.
• Despite a 44.16% rise over the last year, investors are questioning whether BSX presents a better value proposition compared to other stocks in the Medical Products sector.
• The recent bearish movement seems to stem from profit-taking following significant prior gains, as investors reevaluate the company's value and growth potential vis-à-vis competitors like Phibro Animal Health (PAHC).

06.07.2025 - BSX Stock was down 2.2%

• The bearish movement in BSX today could be attributed to investors comparing the stock with GE HealthCare Technologies (GEHC) and potentially finding more value in the latter.
• The overly optimistic views of Wall Street analysts on BSX might have raised concerns among investors about the stock's actual performance, leading to a sell-off.
• Investors may have also reacted to broader market trends or specific industry news impacting medical product companies, causing a negative sentiment towards BSX in today's trading session.

08.00.2025 - BSX Stock was up 5.2%

• Boston Scientific's recent acquisition of Bolt Medical for over $440 million has expanded its cardiovascular treatment portfolio, showcasing growth and innovation in its offerings.
• Achieving a 52-week high reflects strong investor confidence and indicates potential for further gains going forward.
• Despite market fluctuations, Boston Scientific's resilience and positive performance highlight its strength and attractiveness to investors.
• The ongoing sales growth in endoscopy operations beyond the U.S. demonstrates Boston Scientific's adeptness in navigating competition and sustaining a competitive advantage in the market.

08.00.2025 - BSX Stock was up 6.2%

• BSX stock closed at $91.29 today, marking a +0.66% increase from the previous trading day.
• The positive movement in BSX stock is linked to the company's successful expansion internationally, especially in the field of endoscopy, which is anticipated to boost sales.
• Despite a downturn in the overall market, Boston Scientific showed strength, indicating resilience and potential growth in the near future.
• Market sentiment positions BSX as one of the standout performers in non-tech sectors for 2024, showing investor confidence in its future.

25.01.2025 - BSX Stock was down 3.2%

• Despite Boston Scientific's positive outlook for 2025 with expected strong revenue growth, the market might have reacted negatively due to concerns about potential challenges or uncertainties in achieving these ambitious targets.
• Investors may have been expecting even higher growth projections or may have been disappointed by other factors not mentioned, leading to the bearish movement in BSX stock.
• It's possible that profit-taking or a broader market correction influenced the stock's decline, overshadowing the positive expectations for the company's performance in the near future.

02.06.2025 - BSX Stock was down 2.5%

• BSX, having outpaced market performance recently, saw a downturn in its stock value.
• Comparisons to peers such as PAHC and MDT may have contributed to investor apprehension about BSX's future trajectory.
• Intensified competition from Medtronic within the MedSurg segment potentially prompted doubts regarding BSX's market stance and growth opportunities.
• Investors appeared to revisit their perspectives on BSX's value proposition, resulting in today's bearish market activity.

10.03.2025 - BSX Stock was up 7.5%

• BSX stock surged 6.8% in a bullish movement today.
• The positive price movement could be attributed to the market's optimism about the company's future growth prospects.
• Despite a recent drop in share price and earnings estimate revisions, investors seem to be confident in BSX's long-term potential, possibly driven by successful product developments or strategic partnerships.
• The overall bullish sentiment towards BSX today may indicate that investors believe in the company's ability to deliver strong financial performance in the coming periods.

23.03.2025 - BSX Stock was up 5.5%

• BSX stock demonstrated significant bullish momentum recently.
• The company disclosed Q1 earnings and revenues that exceeded expectations, signaling robust financial results.
• Market participants seem to be responding favorably to the strong performance, displaying trust in Boston Scientific's potential for growth.
• The impressive earnings and revenue figures are likely fueling heightened investor confidence and enthusiasm for the stock, contributing to its current upward trajectory.

23.03.2025 - BSX Stock was up 5.5%

• Boston Scientific Corporation (BSX) raised its annual outlook after reporting strong sales in heart devices in Q1, beating revenue and earnings estimates.
• The company's cardiovascular sales saw significant growth, particularly in cardiology products, which contributed to the overall positive performance.
• The stock price surged as investors reacted positively to the company's robust Q1 earnings and revenue results, leading to an optimistic outlook for the future.
• Boston Scientific's solid product portfolio and financial performance in Q1 2025 have instilled confidence in investors, driving the stock price higher.

07.02.2025 - BSX Stock was down 5.1%

• The decline in BSX stock was influenced by doubts surrounding the excessively positive views from Wall Street, causing investors to question the stock's true value and associated risks.
• Despite acquiring SoniVie for $400 million to enhance its hypertension treatment portfolio, there are concerns about the impact on BSX's 2025 EPS, possibly affecting its short-term financial performance and outlook.
• Market uncertainties about integrating SoniVie into Boston Scientific's operations and realizing the expected benefits might be driving a cautious investor sentiment.

10.03.2025 - BSX Stock was down 5.3%

• Analysts view BSX as a promising investment, yet the stock saw a decline, possibly linked to investors capitalizing on profits.
• Following a notable increase in BSX's share price in the previous session, today's drop suggests a shift in market sentiment.
• The stock price of BSX declined by 1.55%, potentially due to investors seizing the opportunity to secure profits following the recent upsurge.